Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08WTE
|
|||
| Former ID |
DIB007488
|
|||
| Drug Name |
Vorsetuzumab mafodotin
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64] | Discontinued in Phase 1 | [1] | |
| Company |
Seattle Genetics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CD70 antigen (CD27-L) | Target Info | . | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| RANKL Signaling Pathway | ||||
| Reactome | TNFs bind their physiological receptors | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020387) | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 660730). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.